



## **Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination with Pasritamig**

**REDWOOD CITY, Calif., February 4, 2026** -- Coherus Oncology, Inc. (NASDAQ: CHRS) announced today a clinical supply agreement with Johnson & Johnson to evaluate tagmokitug (CHS-114), Coherus Oncology's investigational anti-CCR8 cytolytic monoclonal antibody, in combination with pasritamig, a T-cell engaging bispecific antibody, in a Phase 1b clinical study in patients with metastatic castration-resistant prostate cancer (mCRPC).

"This agreement is representative of our strategy to accelerate development of our pipeline through partnerships and differentiated combinations," said Denny Lanfear, Chairman and Chief Executive Officer at Coherus. "We continue to advance our strategic vision to build a portfolio of first-in-class and best-in-class therapies designed to deliver a step change in survival for patients with difficult-to-treat cancers."

Under the terms of the clinical supply agreement, Johnson & Johnson will provide pasritamig to Coherus, who will be the sponsor of the Phase 1b clinical trial. Johnson & Johnson and Coherus each retain all commercial rights to their respective compounds, including as monotherapy or as combination treatments.

### **About Coherus Oncology**

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head & neck, colorectal and other cancers. The Company's strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations.

Coherus' innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug

(CHS-114) is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit [www.loqtorzi.com](http://www.loqtorzi.com).

## **Forward-Looking Statements**

The statements in this press release include express or implied forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended about Coherus that involve risks and uncertainties relating to future events and the future performance of Coherus. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity,” “likely,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the ability of Coherus’ pipeline to enhance outcomes for cancer patients; expectations about future synergies; projections about growth in sales; expectations for future enrollment in clinical trials; projections about the expansion of indications for LOQTORZI; and the assumptions underlying or relating to such statements.

These forward-looking statements are based on Coherus’ current plans, estimates and projections. Such forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those contemplated in any forward-looking statements. Such risks and uncertainties include, without limitation:

uncertainties about the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, economic performance, indebtedness, financial condition and losses on Coherus' prospects, business and operations in the future; risks and uncertainties in executing collaboration agreements and other joint ventures; risks and uncertainties of conducting clinical trials; the risks of Coherus' dependence on an ability to raise funds, which may not be available on acceptable terms or at all; and risks and uncertainties of any litigation, regulatory actions and other legal proceedings.

All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further discussion of these and other factors that could cause Coherus' future results to differ materially from any forward-looking statements see the section entitled "Risk Factors" in Coherus' Quarterly Report on Form 10-Q for the period ended September 30, 2025, filed with the Securities and Exchange Commission (SEC) on November 6, 2025, as updated by Coherus' subsequent reports filed with the SEC.

LOQTORZI® is a registered trademark of Coherus Oncology, Inc.

©2026 Coherus Oncology, Inc. All rights reserved.

**Coherus Oncology Contact Information:**

For Investors:

Carrie Graham

VP, Investor Relations & Advocacy

[IR@coherus.com](mailto:IR@coherus.com)